Transplant Recipient (Kidney)

4

Review clinical trials related to Transplant Recipient (Kidney). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study on Precision Dosing Strategies of Anti-infective Agents in the Very Early Stage of Kidney Transplantation

This study addresses the clinical problem that reliance on serum creatinine, eGFR or empirical dosing fails to accurately adjust anti-infective doses given rapid renal function shifts within the very early 0-5 days post kidney transplantation. We will systematically analyze dynamic trajectories of renal biomarkers (serum creatinine, cystatin C, urine output and other renal function indices), quantify their quantitative associations with the exposure, clearance and pharmacodynamic target attainment of anti-infectives. Combined with clinical profiles, medication data, TDM results and perioperative factors, a population PK/PD model will be built for patients in the very early post-transplant stage. We will further validate the value of dynamic renal markers for individualized anti-infective dosing. This research provides evidence for shifting from static renal function-based empirical dosing to precision dosing guided by real-time renal changes and drug exposure, supporting optimized anti-infective dosage, enhanced efficacy and medication safety in early kidney transplant recipients.

Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Zhongnan HospitalUpdated: Aug 14, 2026Duration: 1 Week
Eligibility criteria

Aged >= 18 years old; [+5]

Previous kidney transplantation or combined multi-organ transplantation [+5]

Status: Recruiting

Tolerance Through Mixed Chimerism (Sip-Tego)

This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESRD) who do not demonstrate evidence of prior sensitization.

Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Tatsuo Kawai, MD, PhDUpdated: Jul 22, 2026Locations: 1
Eligibility criteria

Male or female 18-65 years of age. [+7]

ABO blood group-incompatible renal allograft [+26]

Status: Recruiting

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.

Participants needed: 114
Trial details
Phase: Phase 4Biological sex: AllType: InterventionalSponsor: Instituto de Investigación Hospital Universitario La PazUpdated: Sep 11, 2025Locations: 1
Eligibility criteria

Participants must be willing and able to provide written informed consent prior... [+4]

Known hypersensitivity/allergy reaction to tacrolimus or any of the excipients. [+4]

Status: Recruiting

Clinical and Immunological Outcomes of Living and Deceased Donor Transplantation

This is a retrospective, prospective, single-centre, non-pharmacological observational study. The primary objective is to investigate the long-term prognosis of the kidney transplant function of different types of donors.

Participants needed: 1,293
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaUpdated: Jan 6, 2025Locations: 1
Eligibility criteria

Age ≥ 18 years. [+2]